When to stop, how to reverse, and when to restart antithrombotic drugs periendoscopically in nonvariceal upper gastrointestinal bleeding

Veitch, 2008, British Society of Gastroenterology; British Committee for Standards in Haematology; British Cardiovascular Intervention Society. Guidelines for the management of anticoagulant and antiplatelet therapy in patients undergoing endoscopic procedures, Gut, 57, 1322, 10.1136/gut.2007.142497 ASGE Standards of Practice Committee, 2009, Management of antithrombotic agents for endoscopic procedures, Gastrointest Endosc, 70, 1060, 10.1016/j.gie.2009.09.040 Dworzynski, 2012, Management of acute upper gastrointestinal bleeding: summary of NICE guidance, Br Med J, 344, e3412, 10.1136/bmj.e3412 Barkun, 2010, International Consensus Upper Gastrointestinal Bleeding Conference Group. International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding, Ann Intern Med, 152, 101, 10.7326/0003-4819-152-2-201001190-00009 Boustière, 2011, European Society of Gastrointestinal Endoscopy. Endoscopy and antiplatelet agents, Endoscopy, 43, 445, 10.1055/s-0030-1256317 Sié, 2011, Arch Cardiovasc Dis, 104, 669, 10.1016/j.acvd.2011.09.001 Slichter, 2007, Platelet transfusion therapy, Hematol Oncol Clin North Am, 21, 697, 10.1016/j.hoc.2007.06.010 McCullough, 2010, Overview of platelet transfusion, Semin Hematol, 47, 235, 10.1053/j.seminhematol.2010.04.001 Ageno W, Gallus AS, Wittkowsky A, et al, Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;144(suppl 2):e44S-e88S. Ansell, 2008, Pharmacology and management of the vitamin K antagonists. American College of Chest Physician. Evidence-based clinical practice guidelines, Chest, 133, 160S, 10.1378/chest.08-0670 Lubetsky, 2003, Impact of pre-treatment INR level on the effect of intravenous low dose vitamin K in patients with excessive anticoagulation, Thromb Haemost, 90, 71, 10.1055/s-0037-1613601 Patriquin, 2011, Treatment of warfarin-associated coagulopathy with vitamin K, Expert Rev Hematol, 4, 657, 10.1586/ehm.11.59 Holland, 2006, Toward rational fresh frozen plasma transfusion: the effect of plasma transfusion on coagulation test results, Am J Clin Pathol, 126, 133, 10.1309/NQXHUG7HND78LFFK Dickneite, 2013, Reversing the new oral anticoagulants with prothrombin complex concentrates (PCCS): what is the evidence?, Thromb Haemost, 111, 189, 10.1160/TH13-05-0431 Franchini, 2010, Prothrombin complex concentrates: an update, Blood Transfus, 8, 149 Leissinger, 2008, Role of prothrombin complex concentrates in reversing warfarin anticoagulation: a review of the literature, Am J Hematol, 83, 137, 10.1002/ajh.21046 Dentali, 2011, Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. A meta-analysis, Thromb Haemost, 106, 429, 10.1160/TH11-01-0052 Cromwell, 2012, FEIBA: a prohemostatic agent, Semin Thromb Hemost, 38, 265, 10.1055/s-0032-1309286 Erlich, 2002, Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events, Haemophilia, 8, 83, 10.1046/j.1365-2516.2002.00532.x O’Connell, 2006, Thromboembolic adverse events after the use of recombinant factor VIIa, J Am Med Assoc, 295, 293, 10.1001/jama.295.3.293 Awad, 2013, Activated prothrombin complex concentrates for the reversal of anticoagulant-associated coagulopathy, P&T, 38, 696 Boustiere, 2011, Endoscopy and antiplatelet agents. European Society of Gastrointestinal Endoscopy (ESGE) guideline, Endoscopy, 43, 445, 10.1055/s-0030-1256317 Radaellia, 2015, Management of anticoagulation in patients with acute GI bleeding, Dig Liver Dis, 47, 621, 10.1016/j.dld.2015.03.029 Godier, 2015, Inefficacy of platelet transfusion to reverse ticagrelor, N Engl J Med, 372, 196, 10.1056/NEJMc1409373 Judge, 2015, PAR1 antagonists inhibit thrombin-induced platelet activation whilst leaving the PAR4-mediated response intact, Platelets, 26, 236, 10.3109/09537104.2014.902924 Laine, 2012, ACG PRACTICE GUIDELINES: management of patients with ulcer bleeding, Am J Gastroenterol, 107, 345, 10.1038/ajg.2011.480 Antithrombotic Trialists (ATT) Collaboration, 2009, Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomized trials, Lancet, 373, 1849, 10.1016/S0140-6736(09)60503-1 Sung, 2010, Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial, Ann Intern Med, 152, 1, 10.7326/0003-4819-152-1-201001050-00179 Derogar, 2013, Discontinuation of low dose aspirin therapy after peptic ulcer bleeding increases risk of death and acute cardiovascular events, Clin Gastroenterol Hepatol, 11, 38, 10.1016/j.cgh.2012.08.034 Gralnek, 2015, Diagnosis and management of nonvariceal upper gastrointestinal hemorrhage: European Society of Gastrointestinal Endoscopy (ESGE) Guideline, Endoscopy, 47, 1, 10.1055/s-0034-1393172 Abraham, 2010, Am J Gastroenterol, 105, 2533, 10.1038/ajg.2010.445 Burger, 2005, Low-dose aspirin for secondary cardiovascular prevention-cardiovascular risks after its perioperative withdrawal vs bleeding risks with its continuation-review and meta analysis, J Intern Med, 257, 399, 10.1111/j.1365-2796.2005.01477.x Holbrook, 2012, Evidence-based management of anticoagulant therapy: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 141 Grove, 2015, Antiplatelet therapy in acute coronary syndromes, Expert Opin Pharmacother, 16, 2133, 10.1517/14656566.2015.1079619 Guerrouij, 2011, The clinical impact of bleeding during oral anticoagulant therapy: assessment of morbidity, mortality and post-bleed anticoagulant management, J Thromb Thrombolysis, 31, 419, 10.1007/s11239-010-0536-7 Soff, 2012, A new generation of oral direct anticoagulants, Arterioscler Thromb Vasc Biol, 32, 569, 10.1161/ATVBAHA.111.242834 Ansell, 2008, Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, Chest, 133, 160S, 10.1378/chest.08-0670 Watson, 2001, A comparison of the efficacy and rate of response to oral and intravenous Vitamin K in reversal of over-anticoagulation with warfarin, Br J Haematol, 115, 145, 10.1046/j.1365-2141.2001.03070.x Dentali, 2006, Treatment of coumarin-associated coagulopathy: a systematic review and proposed treatment algorithms, J Thromb Haemost, 4, 1853, 10.1111/j.1538-7836.2006.01986.x Garcia, 2010, Practical management of coagulopathy associated with warfarin, Br Med J, 340, c1813, 10.1136/bmj.c1813 Irwin, 2014, Supratherapeutic anticoagulation at presentation is associated with reduced mortality in nonvariceal upper gastrointestinal hemorrhage, Endosc Int Open, 2, E148, 10.1055/s-0034-1377287 Jairath, 2012, National audit of the use of surgery and radiological embolization after failed endoscopic haemostasis for non-variceal upper gastrointestinal bleeding, Br J Surg, 99, 1672, 10.1002/bjs.8932 Choudari, 1994, Acute gastrointestinal haemorrhage in anticoagulated patients: diagnoses and response to endoscopic treatment, Gut, 35, 464, 10.1136/gut.35.4.464 Dentali, 2008, Management of excessive anticoagulant effect due to vitamin K antagonists, Hematology, 26, 6 Nishimura, 2014, AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, Circulation, 2014, e521, 10.1161/CIR.0000000000000031 Keeling, 2011, Guidelines on oral anticoagulation with warfarin, Br J Haematol, 154, 311, 10.1111/j.1365-2141.2011.08753.x Tazarourte, 2014, Guideline-concordant administration of prothrombin complex concentrate and vitamin K is associated with decreased mortality in patients with severe bleeding under vitamin K antagonist treatment (EPAHK study), Crit Care, 18, R81, 10.1186/cc13843 Sarode, 2013, Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study, Circulation, 128, 1234, 10.1161/CIRCULATIONAHA.113.002283 Karaca, 2014, Use and effectiveness of prothrombin complex concentrates vs. fresh frozen plasma in gastrointestinal hemorrhage due to warfarin usage in the ED, Am J Emerg Med, 32, 660, 10.1016/j.ajem.2014.02.016 Hickey, 2013, Outcomes of urgent warfarin reversal with frozen plasma versus prothrombin complex concentrate in the emergency department, Circulation, 128, 360, 10.1161/CIRCULATIONAHA.113.001875 Sarode, 2013, Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study, Circulation, 128, 1234, 10.1161/CIRCULATIONAHA.113.002283 Leissinger, 2008, Role of prothrombin complex concentrates in reversing warfarin anticoagulation: a review of the literature, Am J Hematol, 83, 137, 10.1002/ajh.21046 Sarode, 2013, Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study, Circulation, 128, 1234, 10.1161/CIRCULATIONAHA.113.002283 Holland, 2009, Suboptimal effect of a three-factor prothrombin complex concentrate (Profilnine-SD) in correcting supratherapeutic international normalized ratio due to warfarin overdose, Transfusion, 49, 1171, 10.1111/j.1537-2995.2008.02080.x Milling, 2016, Thromboembolic events after vitamin K antagonist reversal with 4-factor prothrombin complex concentrate: exploratory analyses of two randomized, plasma controlled studies, Ann Emerg Med, 67, 96, 10.1016/j.annemergmed.2015.04.036 Evans, 2008, Emergency warfarin reversal with prothrombin complex concentrates: UK wide study, Br J Haematol, 141, 268, 10.1111/j.1365-2141.2008.07031.x Witt, 2012, Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for gastrointestinal tract bleeding, Arch Intern Med, 172, 1484, 10.1001/archinternmed.2012.4261 Lee, 2012, Risks related with withholding and resuming anticoagulation in patients with non-variceal upper gastrointestinal bleeding while on warfarin therapy, Int J Clin Pract, 66, 64, 10.1111/j.1742-1241.2011.02827.x Qureshi, 2014, Restarting anticoagulation and outcomes after major gastrointestinal bleeding in atrial fibrillation, Am J Cardiol, 113, 662, 10.1016/j.amjcard.2013.10.044 Douketis, 2012, Perioperative management of antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 114, e326S Baron, 2014, New anticoagulant and antiplatelet agents: a primer for the gastroenterologist, Clin Gastroenterol Hepatol, 12, 187, 10.1016/j.cgh.2013.05.020 Heidbuchel, 2013, European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation, Europace, 15D5, 625, 10.1093/europace/eut083 Schulman, 2009, Dabigatran versus warfarin in the treatment of acute venous thromboembolism, N Engl J Med, 361, 2342, 10.1056/NEJMoa0906598 Connolly, 2009, Dabigatran versus warfarin in patients with atrial fibrillation, N Engl J Med, 361, 1139, 10.1056/NEJMoa0905561 Granger, 2011, Apixaban versus warfarin in patients with atrial fibrillation, N Engl J Med, 365, 981, 10.1056/NEJMoa1107039 Giugliano, 2013, Edoxaban versus warfarin in patients with atrial fibrillation, N Engl J Med, 369, 2093, 10.1056/NEJMoa1310907 Patel, 2011, Rivaroxaban versus warfarin in nonvalvular atrial fibrillation, N Engl J Med, 365, 883, 10.1056/NEJMoa1009638 Graham, 2015, Cardiovascular, bleeding, and mortality risks in elderly medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation, Circulation, 131, 157, 10.1161/CIRCULATIONAHA.114.012061 Piccini, 2014, Management of major bleeding events in patients treated with rivaroxaban vs warfarin: results from the ROCKET AF trial, Eur Heart J, 35, 1873, 10.1093/eurheartj/ehu083 Healey, 2012, Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the randomized evaluation of long-term anticoagulation therapy (RE-LY) randomized trial, Circulation, 126, 343, 10.1161/CIRCULATIONAHA.111.090464 Hylek, 2014, Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: the ARISTOTLE trial (apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation):predictors, characteristics, and clinical outcomes, J Am Coll Cardiol, 63, 2141, 10.1016/j.jacc.2014.02.549 Desai, 2013, Novel oral anticoagulants in gastroenterology practice, Gastrointest Endosc, 78, 227, 10.1016/j.gie.2013.04.179 Pollack, 2015, Idarucizumab for dabigatran reversal, N Engl J Med, 373, 511, 10.1056/NEJMoa1502000 Stangier, 2010, Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate, Clin Pharmacokinet, 49, 259, 10.2165/11318170-000000000-00000 Chai-Adisaksopha, 2015, Hemodialysis for the treatment of dabigatran-associated bleeding: a case report and systematic review, J Thromb Haemost, 13, 1790, 10.1111/jth.13117 Scaglione, 2013, New oral anticoagulants: comparative pharmacology with vitamin K antagonists, Clin Pharmacokinet, 52, 69, 10.1007/s40262-012-0030-9 Cuker, 2014, Laboratory measurement of the anticoagulant activity of the nonvitamin K oral anticoagulants, J Am Coll Cardiol, 64, 1128, 10.1016/j.jacc.2014.05.065 Cuker, 2016, Laboratory measurement of the nonvitamin K antagonist oral anticoagulants:selecting the optimal assay based on drug, assay availability, and clinical indication, J Thromb Thrombolysis, 41, 241, 10.1007/s11239-015-1282-7 Liew, 2013, Assessment of anticoagulation intensity and management of bleeding with old and new oral anticoagulants, Can J Cardiol, 29, S34, 10.1016/j.cjca.2013.04.013 Hawes, 2013, Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels, J Thromb Haemost, 11, 1493, 10.1111/jth.12308 Harenberg, 2016, Measurement of dabigatran, rivaroxaban and apixaban in samples of plasma, serum and urine, under real life conditions. An international study, Clin Chem Lab Med, 54, 275, 10.1515/cclm-2015-0389 Cuker, 2015, Laboratory measurement of the anticoagulant activity of edoxaban: a systematic review, J Thromb Thrombolysis, 39, 288, 10.1007/s11239-015-1185-7 Morishima, 2015, Laboratory measurements of the oral direct factor xa inhibitor edoxaban: comparison of prothrombin time, activated partial thromboplastin time, and thrombin generation assay, Am J Clin Pathol, 143, 241, 10.1309/AJCPQ2NJD3PXFTUG Di, 2015, Antithrombotic drugs, patient characteristics, and gastrointestinal bleeding: clinical translation and areas of research, Blood Rev, 29, 335, 10.1016/j.blre.2015.03.004 Siegal, 2014, How I treat target-specific oral anticoagulant-associated bleeding, Blood, 123, 1152, 10.1182/blood-2013-09-529784 Heidbuchel, 2013, European heart and rhythm association practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation, Europace, 15, 625, 10.1093/europace/eut083 Aisenberg, 2016, The specific direct oral anticoagulant reversal agents: their current status and future place in gastroenterology practice, Am J Gastroenterol Suppl, 3, 36, 10.1038/ajgsup.2016.6 Pollack, 2015, Idarucizumab for dabigatran reversal, N Engl J Med, 373, 511, 10.1056/NEJMoa1502000 Eikelboom, 2015, Idarucizumab: the antidote for reversal of dabigatran, Circulation, 132, 2412, 10.1161/CIRCULATIONAHA.115.019628 Pollack, 2015, Initial results of the reverse ad trial: idarucizumab reverses the anticoagulant effects of dabigatran in patients in an emergency setting of major bleeding, urgent surgery or interventions, Emerg Med J, 32, 979, 10.1136/emermed-2015-205372.9 Chatterjee, 2016, Assessment and management of gastrointestinal hemorrhage in the setting of direct oral anticoagulants: the hematology perspective, Am J Gastroenterol Suppl, 3, 29, 10.1038/ajgsup.2016.5 Ansell, 2014, Use of PER977 to reverse the anticoagulant effect of edoxaban, N Engl J Med, 371, 2141, 10.1056/NEJMc1411800 Siegal, 2015, Andexanet alfa for the reversal of factor Xa inhibitor activity, N Engl J Med, 373, 2413, 10.1056/NEJMoa1510991 Kahn, 2016, Risks to reversal of anticoagulation: the cardiology perspective, Am J Gastroenterol Suppl, 3, 22, 10.1038/ajgsup.2016.4 Ansell, 2014, Use of PER977 to reverse the anticoagulant eff ect of edoxaban, N Engl J Med, 371, 2141, 10.1056/NEJMc1411800 Douketis, 2015, Perioperative bridging anticoagulation in patients with atrial fibrillation, N Engl J Med, 373, 823, 10.1056/NEJMoa1501035 Abraham, 2016, Prevention of gastrointestinal bleeding in patients receiving direct oral anticoagulants, Am J Gastroenterol Suppl, 3, 2, 10.1038/ajgsup.2016.2 Heidbuchel, 2013, European heart rhythm association practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation, Europace, 15, 625, 10.1093/europace/eut083 Hernandez, 2015, Risk of bleeding with dabigatran in atrial fibrillation, JAMA Intern Med, 175, 18, 10.1001/jamainternmed.2014.5398 Abraham, 2015, Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: Population based cohort study, Br Med J, 350, h1857, 10.1136/bmj.h1857